Lipoglycopeptide

Source: Wikipedia, the free encyclopedia.
Lipoglycopeptide
J01XA
Mode of actionBacterial cell wall disruption
Mechanism of actionInhibit peptidoglycan glycosyltransferase chain elongation
Legal status
In Wikidata

Lipoglycopeptides are a class of

lipophilic side-chains linked to glycopeptides. The class includes oritavancin, telavancin and dalbavancin.[1][2]

In September 2009 the US Food and Drug Administration (FDA) approved telavancin (Vibativ) for complicated skin and skin structure infections (cSSSI) On May 23, 2014, the FDA approved dalbavancin (Dalvance), an injectable drug, administered intravenously in two doses one week apart. On August 6, 2014, the FDA approved oritavancin (Orbactiv), an injectable drug administered as a single dose to comprise a full course of therapy.

Telavancin is the most potent of the three against Clostridium spp.[3]

Approvals and clinical trials

complicated skin and skin structure infections (cSSSI).[6]

Oritavancin (once daily injection)[4] has completed phase II and phase III trials. [7][8][9] Oritavancin was approved by the FDA on August 6, 2014, and by the EMA mid-2015, for treatment of acute bacterial skin and skin structure infections (ABSSSI).[10][11]

Generating Antibiotic Incentives Now
(GAIN) title of the FDA Safety and Innovation Act, dalbavancin was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections. As part of its QIDP designation, dalbavancin was given priority review, which provides an expedited review of the drug's application. dalbavancin's QIDP designation also qualifies it for an additional five years of marketing exclusivity to be added to certain exclusivity periods already provided by the Food, Drug and Cosmetic Act.

See also

References

  1. PMID 15700951
    .
  2. ^ "Fight Against Antimicrobial Resistance Recruiting New Agents". 1 Feb 2011.
  3. S2CID 207298905
    .
  4. ^
    PMID 16955686
    .
  5. ^ "CTG Labs - NCBI".
  6. ^ "Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections" (Press release). Theravance, Inc. and Astellas Pharma US, Inc. 2009-09-11. Retrieved September 16, 2009.
  7. ^ "Nuvocid® (Oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)". 13 August 2008.
  8. PMID 25709561
    .
  9. PMID 29358292
    .
  10. ^ "FDA approves Orbactiv to treat skin infections". www.fda.gov. Archived from the original on 2014-08-08.
  11. ^ "Tenkasi (Previously Orbactiv)". 17 September 2018.
  12. ^ "Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections with Suspected or Confirmed Gram-Positive Bacterial Pathogens". 23 June 2005.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lipoglycopeptide&oldid=1259380459"